I think what we need is marketing. The company is doing extremely well on the execution front but unless they commit time to market their achievements and tell the story to investors, we will remain illiquid and undervalued. Roadshows, corporate presos, etc..
tell an insto about the technology, contracts in hand and market opportunity plus cash reserves and they would jump into it straight away. The current SP is back to where it was for the average of 1H.. meaning the new contracts with Labcon have been ignored by investors. what a great entry point.. But if you dont tell them they will never find out about it. Something that can be done and shared by Mngt and Board.
This should be comfortably trading in the 10-15cps rather than 5-6cps. But again, no sizable investor will find out about it on their own. A piece of constructive criticism.
- Forums
- ASX - By Stock
- BCT
- BCT 2.019
BCT 2.019, page-24
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BCT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.737M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BCT (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online